HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a $13 price target on the stock.
November 15, 2023 | 3:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals and maintained a $13 price target.
The reiteration of a Buy rating and the maintenance of a $13 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on ACXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100